Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health IT Groups Praise Goals Of Draft EHR Bill, But Question Mandates

This article was originally published in The Gray Sheet

Executive Summary

Electronic health records would have to be coordinated enough for users to view results of patient tests, see registry information, and access device data under a Senate HELP Committee draft bill calling for federal standards, but health IT groups say they would prefer a more voluntary approach.

You may also be interested in...

Senate Will Tackle Separate Device Reform Bills As Part Of Innovation Agenda

Multiple bills focused on accelerating the path to market for devices will join safety legislation reforming the regulation of duodenoscopes in a slate of Senate bills that HELP Committee Chairman Lamar Alexander said will receive hearings in February, March and April. The legislation-by-legislation approach in the Senate differs from the broad-based 21st Century Cures package that advanced in the House.

Clinical Registries Need Streamlining To Reap Benefits, Mussallem Tells Congress

Clinical registries can yield useful information on patient outcomes that can support approval, reimbursement and care decisions but the benefits of registries need to be balanced against their costs, Edwards Lifesciences CEO Michael Mussalem told a House Energy and Commerce subcommittee July 22.

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts